Jacques Simard

researcher

Jacques Simard is …
instance of (P31):
humanQ5

P735given nameJacquesQ941049
JacquesQ941049
P106occupationresearcherQ1650915
P21sex or gendermaleQ6581097

Reverse relations

author (P50)
Q73497041(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen
Q4644887317alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister
Q3370212417beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes
Q59355837A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
Q28200053A candidate prostate cancer susceptibility gene at chromosome 17p
Q63363987A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening
Q34015399A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics
Q30541811A focus group study on breast cancer risk presentation: one format does not fit all
Q37619303A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium
Q35089479A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
Q40368809A new alternative splice variant of BRCA1 containing an additional in-frame exon
Q34150380A new insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency
Q36152991A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers
Q73867030A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty
Q36043159ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry
Q37417780AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study
Q42459420Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells
Q70030542Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs
Q36073563An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression
Q35618307An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers
Q39848414Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer
Q43738941Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer
Q41583427Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Q68078523Androgens and breast cancer
Q69449188Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer
Q51051999Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?
Q35242849Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers
Q28290684Assignment of the gene encoding the catalytic subunit C beta of cAMP-dependent protein kinase to the p36 band on chromosome 1
Q45979098Association analysis identifies 65 new breast cancer risk loci.
Q36072765Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study
Q36178189Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Q37684672Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.
Q37268494Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry
Q34801008Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q35957703Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
Q35523236Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
Q57056093Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
Q42486668Atrial natriuretic factor does not affect basal, forskolin- and CRF-stimulated adenylate cyclase activity, cAMP formation or ACTH secretion, but does stimulate cGMP synthesis in anterior pituitary
Q42509271Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion
Q34480647BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
Q24672715BRCA1 mutations in Ashkenazi Jewish women
Q37002955BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Q71167609BRCA2 germline mutations in male breast cancer cases and breast cancer families
Q42443275Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells
Q42363834Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers
Q34873841Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec
Q35940158Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Q36998293COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration
Q25257341CYP17 and breast cancer: no overall effect, but what about interactions?
Q34963894Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q48368446Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues
Q42473124Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.
Q42486954Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture
Q40607915Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells
Q40034935Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer
Q44460221Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians
Q34543730Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta
Q28294307Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells
Q33587551Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate
Q42445585Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro
Q33222849Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads
Q67901776Characterization of the structure-activity relationships of rat types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5 -delta 4 isomerase by site-directed mutagenesis and expression in HeLa cells
Q35169450Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17.
Q59238197Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation
Q36754871Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation
Q40508451Codon 367 polymorphism of the human type I 3 beta-hydroxysteroid dehydrogenase/isomerase gene (HS5DB3).
Q40873316Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy
Q39697074Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience
Q36839777Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
Q34394665Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction
Q35889575Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Q24655824Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q34379032Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium
Q42691997Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families
Q36393232Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
Q35870067Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q37434133Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
Q34213403Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers
Q41194578Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations
Q42550093Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters
Q44033897Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin
Q34158693Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency
Q28184736Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene
Q31875103Crucial role of cytokines in sex steroid formation in normal and tumoral tissues
Q34310104DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology
Q40967909DHEA and peripheral androgen and estrogen formation: intracinology
Q50883727DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging.
Q21144874DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers
Q34337035Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency
Q72449361Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians
Q44500270Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13).
Q34356126Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21.
Q58546894Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Q71996206Dinucleotide repeat polymorphisms in the HSD3B2 gene
Q52682549Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada).
Q48524479Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues.
Q51554509Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?
Q42496991Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line
Q33694914EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
Q34535264EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium
Q51798328Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
Q69040335Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture
Q53243537Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing.
Q38022181Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population
Q69093411Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in-situ hybridization
Q69581264Electron microscopic autoradiographic localization of prolactin mRNA in rat pituitary
Q35109610Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone
Q73583253Estimated potency of Casodex: a problematic design
Q37004792Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer
Q33614244Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
Q37481884Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).
Q36352389Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers
Q54655246Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Q35064451Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
Q37342144Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation
Q37102122Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk
Q67864891Expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) in adipose tissue
Q68060223Expression of liver-specific member of the 3 beta-hydroxysteroid dehydrogenase family, an isoform possessing an almost exclusive 3-ketosteroid reductase activity
Q37594336FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium
Q43940234Family communication following BRCA1/2 genetic testing: a close look at the process
Q37236216Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).
Q36111237Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus
Q36087170Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Q35524465Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.
Q61230414Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes
Q39844032Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer
Q36248936Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk
Q34903062Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Q37367871Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
Q34325442Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family
Q44652368From the gene to the clinic: prostate cancer death can now be an exception?
Q42506316Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs
Q64087937Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control
Q39308016Functional analysis of promoter variants in KU70 and their role in cancer susceptibility
Q34317013Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia.
Q36124728Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
Q36742577Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers
Q40137431Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium
Q28290206Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13
Q34570037Genetic discrimination and life insurance: a systematic review of the evidence
Q72457355Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locus
Q34372778Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region
Q71379341Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22
Q70484903Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA
Q35925620Genetic predisposition to ductal carcinoma in situ of the breast
Q35151684Genetic predisposition to in situ and invasive lobular carcinoma of the breast
Q46944912Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer
Q35022825Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers
Q35179897Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
Q34378972Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
Q36422109Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium
Q30000080Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent
Q28388497Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types
Q35996692Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
Q63681757Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Q24622610Genome-wide association studies identify four ER negative-specific breast cancer risk loci
Q27008356Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
Q42812130Genomic organization and expression of the mouse Brca2 gene
Q38361077Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene
Q36113782Gonadotropin-releasing hormone agonists in the treatment of prostate cancer
Q64092231Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease
Q36276540Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
Q57694680High risk genes predisposing to prostate cancer development—do they exist?
Q35102646Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk
Q34321130Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD.
Q30252854Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Q36720814Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk
Q36859142Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
Q36086247Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus
Q34038964Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions
Q35541663Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Q46103372Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Q37378034Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model
Q50061932Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?
Q40979888Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13.
Q40926664Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines
Q51596707Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility.
Q37410472Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women
Q39253143Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer
Q47586106Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia
Q35104068Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer
Q42476332Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer
Q69749114Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland
Q42498354Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells
Q41753997Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells
Q42525215Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells
Q42478497Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells
Q33984042Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease
Q72659351Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer
Q42476720Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells
Q36315402Is dehydroepiandrosterone a hormone?
Q42527246Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs
Q57191573Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair
Q28267893Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
Q29416989Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Q42343135Life insurance: genomic stratification and risk classification
Q24538779Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators
Q47344785Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity
Q51017140Localization and regulation of expression of the FAR-17A gene in the hamster flank organs.
Q48148767Localization of 3 beta-hydroxysteroid dehydrogenase in rat brain as studied by in situ hybridization
Q68889293Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization
Q48045595Localization of BRCA1 gene expression in adult cynomolgus monkey tissues
Q43455041Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(a)antracene (DMBA)-induced mammary tumors in the rat.
Q34240519Localization of the catalytic subunit C gamma of the cAMP-dependent protein kinase gene (PRKACG) to human chromosome region 9q13.
Q48888669Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis.
Q44439883Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer
Q28301935Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2
Q28183826Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7
Q38226150Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians' practices in primary care settings
Q34497352MicroRNA related polymorphisms and breast cancer risk
Q43735920Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland
Q57306222Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families
Q34350282Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Q34325834Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency.
Q40454994Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency.
Q34409441Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family
Q28301131Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family
Q35635695Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase
Q24314861Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase
Q48873935Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus.
Q72315005Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver
Q48256289Multiple factors controlling ACTH secretion at the anterior pituitary level
Q36897003Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Q34268894Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues
Q50335703Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients.
Q33258847Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families
Q46677306Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer
Q33677871Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites
Q49024646Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations.
Q39991531Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families
Q39671238New concepts on the androgen sensitivity of prostate cancer.
Q73276373New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enz
Q37237352No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study
Q30374367No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Q47154249No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families
Q39357672No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result
Q72879118No evidence of mutations in the genes for type I and type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) in nonclassical 3 beta HSD deficiency
Q34299781Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene
Q35752042Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
Q63328929Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract
Q28565172Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization
Q34252341Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis
Q42482863Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells
Q28577186Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin
Q43622332Ovarian 3 beta-hydroxysteroid dehydrogenase and sulfated glycoprotein-2 gene expression are differentially regulated by the induction of ovulation, pseudopregnancy, and luteolysis in the immature rat
Q36280191Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Q28584533PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Q47143943PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1.
Q36417799Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges
Q35737888Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Q36543050Personalized medicine and access to health care: potential for inequitable access?
Q34646957Perspective: prostate cancer susceptibility genes
Q62583133Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Q36066735Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Q34780052Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q47590869Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics
Q68823228Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells
Q42491925Potent stimulatory effect of interleukin-1 alpha on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells
Q36356727Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
Q37487782Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry
Q36583004Prediction of breast cancer risk based on profiling with common genetic variants
Q62583372Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
Q35147120Prostate cancer susceptibility genes: lessons learned and challenges posed
Q55508030Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
Q34236652Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities
Q56603155Purification, Cloning, Complementary DNA Structure, and Predicted Amino Acid Sequence of Human Estradiol 17?-Dehydrogenase
Q36512097RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies
Q36009422RAD51B in Familial Breast Cancer
Q72430442Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat
Q57316334Rapid restriction fragment analysis for screening four point mutations of the Low-density lipoprotein receptor gene in French Canadians
Q37524981Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies
Q67676261Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolacti
Q67589635Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormones
Q48319138Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture
Q69263997Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats
Q42484821Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer
Q41017480Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells
Q60895483Relative potencies of Flutamide and Casodex: preclinical studies
Q44884896Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study
Q54309392Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium.
Q48545504Return of research results: general principles and international perspectives.
Q38717239Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Q34089016Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues
Q40632768SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation
Q36545934SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival
Q40662263Science behind total androgen blockade: from gene to combination therapy
Q61118451Shared heritability and functional enrichment across six solid cancers
Q64004349Shared heritability and functional enrichment across six solid cancers
Q28248401Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate
Q41669474Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells
Q42511463Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture
Q24310592Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads
Q67882522Structure and expression of the genes encoding the enzymes for ovarian and peripheral steroidogenesis
Q31138125Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues
Q28572734Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skin
Q28253733Structure of human type II 5 alpha-reductase gene
Q31110971Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2.
Q34118459Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues
Q40707753Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues
Q70862262Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family
Q40914971Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency.
Q43076184Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators
Q44044839Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor
Q41473936Synthesis and antiestrogenic activity of diaryl thioether derivatives
Q34428008Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution.
Q68412019Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate
Q37122297Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
Q33675997The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q64116004The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations
Q37578078The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers
Q37401496The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q62583294The association between low-density lipoprotein cholesterol predicted by HMGCR genetic variants and breast cancer risk may be mediated by body mass index
Q60487433The association between weight at birth and breast cancer risk revisited using Mendelian randomisation
Q64239462The association between weight at birth and breast cancer risk revisited using Mendelian randomisation
Q41226231The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
Q58674081The emergence of an ethical duty to disclose genetic research results: international perspectives
Q72449349The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21
Q28288526The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species
Q28303450The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology
Q38967942The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes
Q45784223Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families
Q53251612Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility.
Q39672610Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers
Q38814549VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis
Q41110061Variations of pre-proNPY mRNA in the arcuate nucleus during the rat estrous cycle
Q72409585Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey
Q72231232["Intracrinology". Autonomy and freedom of peripheral tissues]
Q39728256p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6.
Q37414133rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk

Search more.